ReviewVascular health and risk management2026
Obesity-Associated Cardiac Fibrosis: Mechanisms and Emerging Therapeutic Targets.
Review in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and cardiovascular disease are major, globally prevalent, and closely interrelated health challenges. Cardiac fibrosis represents the common pathological endpoint of multiple cardiac diseases. This review systematically synthesizes the mechanisms underlying obesity‑related cardiac fibrosis. It elaborates on how inflammatory factors, cytokines, and miRNAs, acting on adipose tissue and cardiac cells, drive a series of biological processes-including oxidative stress, activation of the renin‑angiotensin‑aldosterone system, autophagy dysregulation, and metabolic dysfunction-ultimately leading to obesity‑associated cardiomyopathy characterized by ventricular remodeling, heart failure, and atrial fibrillation. Potential therapeutic targets for this condition are also examined. Furthermore, this review discusses potential therapeutic targets for this condition, which will provide a critical theoretical foundation for the development of novel strategies aimed at preventing or even reversing obesity‑related fibrotic heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.